MeSH tree: C04.557.450
Uterine fibroids and endometriosis are two of the most common gynecologic diseases, affecting 15% to 80% of women of childbearing age. Existing treatments—hormonal drugs and selective estrogen receptor modulators—have side ...
A research team from the Germans Trias i Pujol Research Institute (IGTP) has developed a new experimental model based on induced pluripotent stem cells (iPSCs) that makes it possible to reproduce in the laboratory the progression ...
Jun 22, 2026
0
4
Endometriosis and uterine fibroids are two of the most common gynecological conditions. While they have important differences, they also have things in common. Both can lead to serious complications, affect fertility and ...
Jun 11, 2026
0
5
A cancer researcher at the University of Houston is reporting what makes malignant soft tissue cancer grow in children, identifying key mechanisms and molecular targets to prevent tumor progression in patients in future therapies ...
Jun 9, 2026
0
6
A new end-to-end PET imaging approach for osteosarcoma can rapidly and reliably distinguish tumor tissue from normal tissue and accurately assess surgical margins in real time. The novel platform, presented at the Society ...
Jun 2, 2026
0
1
Specific genetic fusion patterns in solitary fibrous tumors may help identify which patients face a higher risk of metastasis, recurrence and more aggressive disease behavior, according to new research that could improve ...
May 22, 2026
0
5
A new study has uncovered a genetic cause that may explain why some people develop Kaposi sarcoma despite having no apparent immune deficiency. The rare cancer, which forms in the cells lining blood vessels, is caused by ...
May 14, 2026
0
4
In a breakthrough poised to reshape cancer treatment, Houston Methodist has developed the first personalized mRNA cancer vaccine designed to prevent recurrence of osteosarcoma, a rare and aggressive type of bone cancer. This ...
May 13, 2026
0
19
Rare neuromuscular diseases often lack treatments because developing targeted drugs is slow, costly and risky for companies. A new approach using AI and stem cell models could finally shift the balance.
May 12, 2026
0
5
Leveraging AI capabilities combined with genetic data led St. Jude Children's Research Hospital investigators to predict new cancer drug targets that carry a limited risk of side effects. For their study, published in Science ...
Apr 30, 2026
0
6
